北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 风湿免疫科  > 期刊论文
学科主题: 临床医学
题名:
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension
作者: Jing, Zhi-Cheng1; Strange, Geoff2; Zhu, Xian-Yang3; Zhou, Da-Xin4; Shen, Jie-Yan5; Gu, Hong6; Yang, Zhen-Kun7; Pan, Xin8; Xiang, Mei-Xiang9; Yao, Hua10; Zhao, Dong-Bao11; Dalton, Brad S.12; Zhang, Zhuo-Li13; Wang, Yong14; Cheng, Xian-Sheng15; Yang, Yue-Jin15
关键词: pulmonary arterial hypertension ; bosentan
刊名: JOURNAL OF HEART AND LUNG TRANSPLANTATION
发表日期: 2010-02-01
DOI: 10.1016/j.healun.2009.09.020
卷: 29, 期:2, 页:150-156
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems ; Respiratory System ; Surgery ; Transplantation
研究领域[WOS]: Cardiovascular System & Cardiology ; Respiratory System ; Surgery ; Transplantation
关键词[WOS]: CONGENITAL HEART-DISEASE ; RECEPTOR ANTAGONIST BOSENTAN ; EISENMENGER-SYNDROME ; EXERCISE CAPACITY ; 1ST-LINE BOSENTAN ; THERAPY ; SURVIVAL ; REGISTRY ; ADULTS ; MANAGEMENT
英文摘要:

BACKGROUND: Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population.

METHODS: We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a chance in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics.

RESULTS: At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary artery pressure and pulmonary vascular resistance decreased (p < 0.01), ana cardiac output increased (p < 0.001). Twelve patients (13%) experienced at least 1 adverse event.

CONCLUSIONS: Bosentan improved exercise capacity, functional class, and cardiopulmonary hemodynamics in this patient cohort and was well tolerated. J Heart Lung Transplant 2010;29:150-6 (C) 2010 International Society for Heart and Lung Transplantation. All rights reserved.

语种: 英语
项目资助者: Actelion Pharmaceuticals
WOS记录号: WOS:000274755700002
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56695
Appears in Collections:北京大学第一临床医学院_风湿免疫科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Guangzhou Gen Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China
2.Beijing Shijitan Hosp, Dept Pulm Vasc Dis, Beijing, Peoples R China
3.Monash Univ, Clayton, Vic 3800, Australia
4.Ruijin Hosp, Dept Cardiol, Shanghai, Peoples R China
5.Tongji Univ, Dept Pulm Circulat, Shanghai Pulm Hosp, Sch Med, Shanghai 200092, Peoples R China
6.Gen Hosp Shenyang Mil Command, Dept Congenital Heart Dis, Shenyang, Peoples R China
7.Fudan Univ, Dept Cardiol, Zhongshan Hosp, Shanghai 200433, Peoples R China
8.Shanghai Jiao Tong Univ, Dept Cardiol, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China
9.Capital Univ Med Sci, Dept Pediat, Beijing Anzhen Hosp, Beijing, Peoples R China
10.Shanghai Jiao Tong Univ, Dept Cardiol, Shanghai Chest Hosp, Sch Med, Shanghai 200030, Peoples R China
11.Zhejiang Univ, Dept Cardiol, Affiliated Hosp 2, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
12.Second Mil Med Univ, Dept Rheumatol, Changhai Hosp, Shanghai, Peoples R China
13.Univ Tasmania, Sch Human Life Sci, Hobart, Tas 7001, Australia
14.Beijing Univ, Dept Rheumatol, Hosp 1, Beijing 100871, Peoples R China
15.Beijing Fu Wai Hosp, Dept Cardiol, Beijing, Peoples R China

Recommended Citation:
Jing, Zhi-Cheng,Strange, Geoff,Zhu, Xian-Yang,et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION,2010,29(2):150-156.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jing, Zhi-Cheng]'s Articles
[Strange, Geoff]'s Articles
[Zhu, Xian-Yang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jing, Zhi-Cheng]‘s Articles
[Strange, Geoff]‘s Articles
[Zhu, Xian-Yang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace